Teleflex Investor Presentation
Appendix D - Tickmarks
A. Restructuring, restructuring related and impairment items - For the year ended December 31, 2011, these charges consisted primarily of pre-tax
restructuring charges. For the years ending December 31, 2016 and 2017, pre-tax restructuring related charges were $14.6 million and $15.3 million,
respectively. For the year ended December 31, 2016, impairment items included (i) a pre-tax, non-cash $41.0 million impairment charge and a $14.9
million reduction in related deferred tax liabilities in connection with discontinuation of an in-process research and development project; (ii) $2.4 million in
pre-tax, non-cash impairment charges related to two properties, one of which was classified as an asset held for sale and (iii) a $0.7 million reduction in
related deferred tax liabilities. There were no impairment items during the year ended December 31, 2017. For the year ended December 31, 2022, pre-
tax restructuring charges were $18.8 million, pre-tax restructuring related charges were $31.9 million; and pre-tax impairment charges were $1.5 million.
B. Acquisition, integration and divestiture related items - For the year ended December 31, 2016, amounts attributable to these activities reflect
reversals related to contingent consideration liabilities, including $8.3 million related to the discontinuation of an in-process research and development
project, and the gain on a sale of assets, somewhat offset by acquisition costs. For the year ended December 31, 2017, the majority of these charges
were related to our acquisitions of Vascular Solutions and NeoTract. For the year ended December 31, 2022, these charges related to the acquisition of
Standard Bariatrics, Inc. and the gain related to a sale of a building.
C.
Other items - In 2011, these charges were due primarily to costs related to the separation of a former executive. For the year ended December 31,
2016, these items included relabeling costs and costs associated with a facility that was exited. For the year ended December 31, 2017, these items
included both gains and losses associated with litigation settlements, the reversal of previously recognized income due to distributor acquisitions related
to Vascular Solutions, the reversal of previously recognized income due to our distributor conversion in China and relabeling costs. For the year ended
December 31, 2022, other items related to charges incurred in connection with a debt extinguishment.
23
23
Teleflex®View entire presentation